Patents by Inventor Leonardo Borras

Leonardo Borras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260337289
    Abstract: Provided are multispecific antigen binding proteins and their individual binding domains that specifically bind to BCMA, CD19 and an immune cell target antigen (e.g., CD3). Also provided are conjugates thereof, pharmaceutical compositions comprising the antigen binding proteins, as well as nucleic acids, recombinant expression vectors and host cells engineered to express such antigen binding proteins. Also disclosed are methods of using the antigen binding proteins in the prevention, and/or treatment of diseases or disorders, in particular B cell related disease such as an autoimmune disease or cancer.
    Type: Application
    Filed: April 21, 2026
    Publication date: October 29, 2026
    Inventors: Leonardo BORRAS, Stephanie JUNGMICHEL, Iuliano Maria LOREDANA, Philipp Robert RICHLE, Fabian Bert SCHEIFELE, Alessio VANTELLINI
  • Publication number: 20260284218
    Abstract: Described herein are antigen binding proteins targeting KK-LC-1 derived peptide-MHCs (pMHCs). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one target peptide binding domain. Methods of treatment with the same are also described.
    Type: Application
    Filed: March 23, 2026
    Publication date: September 24, 2026
    Inventors: Fabian Bert Scheifele, Anna Maria Sobieraj, Nagjie Laila Alijaj, Stephanie Jungmichel, Philip Knobel, Leonardo Borras
  • Publication number: 20260274935
    Abstract: The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Application
    Filed: March 13, 2026
    Publication date: September 17, 2026
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • Patent number: 12600769
    Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: April 14, 2026
    Assignee: Novartis AG
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • Publication number: 20250382357
    Abstract: Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided.
    Type: Application
    Filed: April 3, 2025
    Publication date: December 18, 2025
    Inventors: Leonardo BORRAS, Dominik ESCHER, Stephanie JUNGMICHEL, Christian LEISNER, Philipp Robert RICHLE, Fabian SCHEIFELE
  • Publication number: 20250243266
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: December 24, 2024
    Publication date: July 31, 2025
    Inventors: Leonardo BORRAS, Pankaj GUPTA, Stefan HOERER, Stephanie JUNGMICHEL, Christian LEISNER, Sophia REINDL, Philipp Robert RICHLE, Fabian SCHEIFELE, Anna SOBIERAJ
  • Patent number: 12344663
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: July 1, 2025
    Assignees: CDR-Life AG, Boehringer Ingelheim International GmbH
    Inventors: Leonardo Borras, Pankaj Gupta, Stephanie Jungmichel, Christian Leisner, Philipp Robert Richle, Fabian Scheifele, Anna Sobieraj
  • Publication number: 20250144141
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Application
    Filed: October 17, 2024
    Publication date: May 8, 2025
    Inventors: Stephanie JUNGMICHEL, Fabian Bert SCHEIFELE, Anna Maria SOBIERAJ, Philipp Robert RICHLE, Hannes MERTEN, Leonardo BORRAS, Christian Valdemar Vinge LEISNER
  • Publication number: 20250066462
    Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Application
    Filed: February 7, 2023
    Publication date: February 27, 2025
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • Publication number: 20250002586
    Abstract: Described herein are antigen binding proteins comprising a Fab domain which specifically binds to a cell surface protein of an immune cell, a first pMHC binding domain, and a second pMHC binding domain. Methods of treating cancer or a viral infection with the same are also described.
    Type: Application
    Filed: June 6, 2024
    Publication date: January 2, 2025
    Inventors: Leonardo BORRAS, Stephanie JUNGMICHEL, Hannes MERTEN, Philipp Robert RICHLE, Fabian Bert SCHEIFELE, Anna Maria SOBIERAJ
  • Patent number: 12161673
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Grant
    Filed: September 13, 2023
    Date of Patent: December 10, 2024
    Assignee: CDR-LIFE AG
    Inventors: Stephanie Jungmichel, Fabian Bert Scheifele, Anna Maria Sobieraj, Philipp Robert Richle, Hannes Merten, Leonardo Borras, Christian Valdemar Vinge Leisner
  • Publication number: 20240279344
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Application
    Filed: January 4, 2024
    Publication date: August 22, 2024
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • Publication number: 20240091262
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Application
    Filed: September 13, 2023
    Publication date: March 21, 2024
    Inventors: Stephanie JUNGMICHEL, Fabian Bert SCHEIFELE, Anna Maria SOBIERAJ, Philipp Robert RICHLE, Hannes MERTEN, Leonardo BORRAS, Christian Valdemar Vinge LEISNER
  • Patent number: 11912771
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: February 27, 2024
    Assignee: CDR-LIFE AG
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • Patent number: 11858981
    Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech
  • Publication number: 20230257455
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: December 21, 2022
    Publication date: August 17, 2023
    Inventors: Leonardo BORRAS, Pankaj GUPTA, Stefan HOERER, Stephanie JUNGMICHEL, Christian LEISNER, Sophia REINDL, Philipp Robert RICHLE, Fabian SCHEIFELE, Anna SOBIERAJ
  • Patent number: 11578123
    Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: February 14, 2023
    Assignee: Novartis AG
    Inventors: Leonardo Borras, Tea Gunde, David Urech
  • Publication number: 20220380472
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Application
    Filed: March 9, 2022
    Publication date: December 1, 2022
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • Publication number: 20220259296
    Abstract: Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided.
    Type: Application
    Filed: February 11, 2022
    Publication date: August 18, 2022
    Inventors: Leonardo BORRAS, Dominik ESCHER, Stephanie JUNGMICHEL, Christian LEISNER, Philipp Robert RICHLE, Fabian SCHEIFELE
  • Patent number: 11046757
    Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: June 29, 2021
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech